Barbara Adamo
Research group
- Translational genomics and targeted therapies in solid tumours Accredited researcher (R3A)
Featured publications
-
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Authors:Reference: Cancer Treatment Reviews 2020. -
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
Authors:Reference: Breast Cancer Research 2019. -
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer.
Authors:Reference: Cancer Research 2017. -
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Authors:Reference: Journal Of The National Cancer Institute 2014. -
Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity
Authors:Reference: Scientific Reports 2013. -
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
Authors:Reference: Oncologist 2013. -
Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
Authors:Reference: Plos One 2013. -
Triple-negative breast cancer: an update on neoadjuvant clinical trials
Authors:Reference: International Journal Of Breast Cancer 2012. -
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Authors:Reference: Breast Cancer Research 2011. -
Stratifying triple-negative breast cancer: Which definition(s) to use?
Authors:Reference: Breast Cancer Research 2011.
Featured Projects
-
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer
Principal investigator: Aleix Prat AparicioFunder: Instituto de Salud Carlos IIICode: INT_BCN_Catalyst_18Duration: 01/03/2019 - 28/02/2023 -
Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched
Funder: HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Sede o evento); Fundación Merck SaludDuration: 01/01/2019 - 01/01/2020 -
FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad
Funder: HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Sede o evento); Instituto de Salud Carlos IIIDuration: 01/01/2018 -
Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019
Principal investigator: FAyaFunder: Generalitat de CatalunyaDuration: 01/01/2017 - 01/01/2019 -
Identificación de alteraciones moleculares accionables durante la progresión metastásica del cáncer de mama luminal"Proyectos de investigación en salud. Sociedad Española de Oncología Médica (SEOM).
Funder: SEOMDuration: 01/01/2014